Orpiment |
Low |
In vitro |
Dissolution increase with pH increase |
Lantz et al., 1995, Floroiu et al., 2004
|
|
Low GI absorption |
Hamster |
80% in feces; DMA in urine |
Marafente and Vahter, 1987 |
Reaglar |
4% |
Human |
MMA, DMA in urine |
Koch et al., 2007 |
|
Low |
Rat |
Blood>lung, heart>spleen>liver, kidney |
Wang et al., 2003 |
|
Nanoparticles |
Cell and rat |
Increased bioavailability |
Wu and Ho 2006 |
Arsenic trioxide |
High |
Rabbit |
As 3+ in blood, DMA in liver and lung |
Lin et al., 2005 |
|
|
Human |
60% of iv dose recovery in urine |
Fujisawa et al., 2007 |
|
|
Human |
Oral equals to iv bioavailability |
Kumana et al., 2002 |